Indolent Lymphoma Global Clinical Trials Review, H1, 2014

Indolent Lymphoma Global Clinical Trials Review, H1, 2014

Feb 2014 GlobalData Lymphoma154 Pages Price :
$ 2500

GlobalData\'s clinical trial report, Indolent Lymphoma Global Clinical Trials Review, H1, 2014\" provides data on the Indolent Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Indolent Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Indolent Lymphoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData\'s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Indolent Lymphoma 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Indolent Lymphoma to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Indolent Lymphoma to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Indolent Lymphoma 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Indolent Lymphoma Therapeutics Clinical Trials 30
Prominent Drugs 31
Latest Clinical Trials News on Indolent Lymphoma 32
Jan 22, 2014: New drug shows promise in treating indolent non-Hodgkin lymphomas 32
Dec 10, 2013: Studies Evaluating REVLIMID (Lenalidomide) in Lymphoma Presented at ASH 32
Dec 08, 2013: Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkins Lymphoma 34
Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting 35
Aug 17, 2011: Emergent Announces Initiation Of Phase Ib/II Study Of TRU-016 In Combination With Rituximab And Bendamustine In Subjects With Relapsed-Indolent Lymphoma 36
Clinical Trial Profiles 38
Clinical Trial Overview of Top Companies 38
F. Hoffmann-La Roche Ltd. 38
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 38
Gilead Sciences, Inc. 40
Clinical Trial Overview of Gilead Sciences, Inc. 40
Celgene Corporation 41
Clinical Trial Overview of Celgene Corporation 41
Teva Pharmaceutical Industries Limited 42
Clinical Trial Overview of Teva Pharmaceutical Industries Limited 42
Cell Therapeutics, Inc. 43
Clinical Trial Overview of Cell Therapeutics, Inc. 43
GlaxoSmithKline plc 44
Clinical Trial Overview of GlaxoSmithKline plc 44
Sanofi 45
Clinical Trial Overview of Sanofi 45
Pharmacyclics, Inc. 46
Clinical Trial Overview of Pharmacyclics, Inc. 46
Infinity Pharmaceuticals, Inc. 47
Clinical Trial Overview of Infinity Pharmaceuticals, Inc. 47
Bayer AG 48
Clinical Trial Overview of Bayer AG 48
Clinical Trial Overview of Top Institutes / Government 49
National Cancer Institute 49
Clinical Trial Overview of National Cancer Institute 49
The University of Texas M. D. Anderson Cancer Center 50
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 50
Memorial Sloan Kettering Cancer Center 51
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 51
University of Nebraska 52
Clinical Trial Overview of University of Nebraska 52
Fred Hutchinson Cancer Research Center 53
Clinical Trial Overview of Fred Hutchinson Cancer Research Center 53
Hoag Memorial Hospital Presbyterian 54
Clinical Trial Overview of Hoag Memorial Hospital Presbyterian 54
Massachusetts General Hospital 55
Clinical Trial Overview of Massachusetts General Hospital 55
Beth Israel Deaconess Medical Center 56
Clinical Trial Overview of Beth Israel Deaconess Medical Center 56
Virginia Commonwealth University 57
Clinical Trial Overview of Virginia Commonwealth University 57
Ohio State University Comprehensive Cancer Center 58
Clinical Trial Overview of Ohio State University Comprehensive Cancer Center 58
Five Key Clinical Profiles 59

Appendix 151
Abbreviations 151
Definitions 151
Research Methodology 152
Secondary Research 152
About GlobalData 153
Contact Us 153
Disclaimer 153
Source 154

List of Table


Indolent Lymphoma Therapeutics, Global, Clinical Trials by Region, 2014* 7
Indolent Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Indolent Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Indolent Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Indolent Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Indolent Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Indolent Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Indolent Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Indolent Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Indolent Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Indolent Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Indolent Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Indolent Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Indolent Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Indolent Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Indolent Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Indolent Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Indolent Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Indolent Lymphoma Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Indolent Lymphoma Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Indolent Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Indolent Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Indolent Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Indolent Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Indolent Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
Indolent Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 38
Indolent Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Gilead Sciences, Inc., 2014* 40
Indolent Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014* 41
Indolent Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Teva Pharmaceutical Industries Limited, 2014* 42
Indolent Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Cell Therapeutics, Inc., 2014* 43
Indolent Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 44
Indolent Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 45
Indolent Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pharmacyclics, Inc., 2014* 46
Indolent Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Infinity Pharmaceuticals, Inc., 2014* 47
Indolent Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 48
Indolent Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 49
Indolent Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 50
Indolent Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 51
Indolent Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Nebraska, 2014* 52
Indolent Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014* 53
Indolent Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Hoag Memorial Hospital Presbyterian, 2014* 54
Indolent Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 55
Indolent Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Beth Israel Deaconess Medical Center, 2014* 56
Indolent Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Virginia Commonwealth University, 2014* 57
Indolent Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Ohio State University Comprehensive Cancer Center, 2014* 58

List of Chart


Indolent Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Indolent Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Indolent Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Indolent Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Indolent Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Indolent Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Indolent Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Indolent Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Indolent Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Indolent Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Indolent Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Indolent Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Indolent Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Indolent Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Indolent Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Indolent Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Indolent Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Indolent Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Indolent Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Indolent Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Indolent Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Indolent Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
GlobalData Methodology 152

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2500
$ 5000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top